KRAS and neoplasm: In order to assess the anti-tumor effects of dual anti-miR-21 and si-KRAS therapy in PDAC, we treated cells using either TPN-21, TPN-KRAS, or a combination of both and we compared that to TPN-NT (scramble RNA) or double TPN-NT (combo-NT).